NEW YORK (GenomeWeb) – Resolution Bioscience said today that it has made an agreement with Leidos Biomedical Research to evaluate Resolution's liquid biopsy technology.

Under the agreement, the Frederick National Laboratory for Cancer Research, which Leidos operates, will begin using Resolution's "ctDx" sequencing chemistries and bioinformatics pipeline as part of its evaluation of various liquid biopsy technologies.

Financial details of the collaboration were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.